Resource Summary Report

Generated by dkNET on Sep 19, 2026

KG-1a

RRID:CVCL_1824
Type: Cell Line

Proper Citation

RRID:CVCL_1824

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1824

Proper Citation: RRID:CVCL_1824

Description: Cell line KG-1a is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Acute myeloid leukemia without maturation

Defining Citation: PMID:3094604, PMID:6967340, PMID:8558913, PMID:11416159, PMID:22844360, PMID:25877200, PMID:36982453

Comments: Characteristics: Less differentiated subline of KG-1, composed of undifferentiated promyeloblasts., Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KG-1a

Synonyms: KG-1A, KG1A, KG1a

Cross References: BTO:BTO_0005076, CLO:CLO_0007095, CLO:CLO_0051561, CLDB:cl3026, CLDB:cl3027, ATCC:CCL-246.1, BCRC:60224, BioSample:SAMN01821644, BioSample:SAMN03470993, cancercelllines:CVCL_1824, CCRID:1102HUM-NIFDC00028, ChEMBL-Cells:CHEMBL4295408, ChEMBL-Targets:CHEMBL4296453, CLS:300234, Cosmic:787444, Cosmic:821042, Cosmic:850388, Cosmic:985582, Cosmic:994174, Cosmic:1127254, Cosmic:1319553, DSMZ:ACC-421, DSMZCellDive:ACC-421, ECACC:91030101, GEO:GSM1374598, GEO:GSM1446747, IZSLER:BS TCL 196, LINCS_LDP:LCL-1057, Lonza:835, NCBI_Iran:C520, PubChem_Cell_line:CVCL_1824, RCB:RCB1928, TKG:TKG 0402,

Ubigene:YC-C083, Wikidata:Q54899835

ID: CVCL_1824

Hierarchy: cvcl_0374

Record Creation Time: 20220427T220702+0000

Record Last Update: 20260913T004654+0000

Ratings and Alerts

No rating or validation information has been found for KG-1a.

No alerts have been found for KG-1a.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Huang Y, et al. (2026) ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance. iScience, 29(6), 116202.

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. Cancer research, 86(8), 1956.

Han C, et al. (2025) An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance. Blood cancer discovery, 6(5), 464.

Matar S, et al. (2025) Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile. Molecular cancer therapeutics, 24(6), 816.

Tin E, et al. (2025) SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell-Mediated Cytotoxicity. Blood cancer discovery, 6(3), 217.

Sonowal H, et al. (2025) Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia. Cancer research communications, 5(1), 74.

Zoine JT, et al. (2024) Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity. Cell reports. Medicine, 5(2), 101422.

Coleman DJL, et al. (2024) Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1. iScience, 27(4), 109576.

Bianchi M, et al. (2024) The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells. Cancer immunology research, 12(7), 921.

Zhu J, et al. (2024) The AXL inhibitor bemcentinib overcomes microenvironment-mediated resistance to pioglitazone in acute myeloid leukemia. The FEBS journal.

Miari KE, et al. (2023) Stromal bone marrow fibroblasts and mesenchymal stem cells support acute myeloid leukaemia cells and promote therapy resistance. British journal of pharmacology.

van der Werf I, et al. (2023) Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells. Cell reports. Medicine, 4(3), 100962.

Park SM, et al. (2023) Dual IKZF2 and CK1? degrader targets acute myeloid leukemia cells. Cancer cell, 41(4), 726.

Blöchl C, et al. (2023) Transcriptionally imprinted glycomic signatures of acute myeloid leukemia. Cell & bioscience, 13(1), 31.

Wu G, et al. (2023) Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Frontiers in immunology, 14, 1093750.

Chen EC, et al. (2023) Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(5), 878.

Bueno MLP, et al. (2023) The antitumor effects of WNT5A against hematological malignancies. Journal of cell communication and signaling, 17(4), 1487.

Qian Y, et al. (2022) ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD. Molecular oncology.

Jayavelu AK, et al. (2022) The proteogenomic subtypes of acute myeloid leukemia. Cancer cell, 40(3), 301.

Roversi FM, et al. (2022) Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia. Cancer immunology, immunotherapy : CII, 71(8), 1909.